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Abstract
The nature of the cellular immune response to tumors, such as sarcomas is not well understood.
The Arkansas Progessor (AP) and Regressor (AR) chickens maintained at the University of
Arkansas offer unique opportunity to examine anti-tumor immune responses. When injected into
the wing web with Rous sarcoma virus (RSV), chickens from both lines develop tumors which
continue to grow rapidly in AP chickens or regress in AR chickens to the point of elimination.
Little is known concerning the nature of the cellular responses that allow the tumor to escape the
immune system in AP chickens versus the effective anti-tumor response in AR chickens. Using
the growing feather (GF) tissue as a test-site (Erf-US patent U.S. Patent No 8,216,551), the
objective of this study was to monitor cellular immune response to tumor lysates in vivo in the
AP and AR chicken model. Tumor lysates were prepared from a progressing AP and a regressing
AR tumor. Lysates were injected into GF (18 GF/bird) of AP and AR chickens that were not
injected with RSV (unsensitized groups), and in AP and AR chickens with actively progressing
or regressing sarcomas (sensitized groups), respectively (6 birds/group). Injected GF were
collected before (0), and 1, 2, 3, 5, and 7 d post GF-injection for phenotypic cell population
analysis and relative quantitation of responding immune cells. For this, GF pulp cell suspensions
were prepared and immunofluorescently stained using a panel of chicken leukocyte-specific
fluorescently labeled monoclonal antibodies. The proportions of various leukocytes infiltrating
the pulp were determined by flow cytometry. Within the AP and AR groups of chickens, few
temporal, qualitative and quantitative differences in the cellular response were observed between
unsensitized and sensitized groups. This would suggests a relatively weak protective memory
response in both lines. However, side by side comparison of the cellular infiltration response in
AP versus AR chickens points toward a fast and more sustained cell-mediated anti-tumor
effector response in AR compared to AP chickens. The response appears to be ahead of the
tumor in AR chickens and is lagging behind in the AP chickens, resulting in regression and
continued growth of the tumors, respectively. Future studies on functional activities of the tumor
infiltrating cells will provide important insight into effective and ineffective immune responses
to tumors and how tumors evade the immune response.
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List of Abbreviations

AP

Arkansas Progressor Chickens

AR

Arkansas Regressor Chickens

CTL

Cytotoxic Lymphocyte

FSC

Forward Scatter (Size)

GF

Growing Feather

MHC

Major Histocompatibility Complex

NK

Natural Killer Cell

PBS

Phosphate Buffered Saline

RSV

Rous Sarcoma Virus

S-AP

Sensitized Arkansas Progressor

S-AR

Sensitized Arkansas Regressor

SSC

Side Scatter (Complexity)

TCR

T Cell Receptor

U-AP

Unsensitized Arkansas Progressor

U-AR

Unsensitized Arkansas Regressor

v-src

Viral-src
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Introduction

Most vertebrate animals are equipped with two types of immune systems that defend
against harmful microbes: innate and adaptive immunity. Innate immunity is the body’s first and
earliest line of defense against infections. Adaptive immunity is activated later and acts against
pathogens that resist innate immunity. T and B lymphocytes are the cells of adaptive immunity
which are able to focus on small molecular features of antigens using highly specific antigen
receptors. Adaptive immunity takes 7-14 days to develop during a first encounter with a
pathogen (antigen), but the responses are highly specialized to most effectively eliminate the
antigen. Once an adaptive immune response developed, adaptive immunity has the ability to
respond to a previously encountered antigen and react faster, more strongly, more effectively and
with more specificity than the response following initial exposure. This feature of adaptive
immunity is called memory (Abbas et al. 2015). Adaptive immunity includes two types: humoral
immunity mediated by B-lymphocytes, and cell-mediated immunity mediated by T-lymphocytes.
Both innate and adaptive immunity involve a complex system of numerous cells and cellular
responses to pathogens and cellular abnormalities, such as cancer cells.
Cancer is a highly prevalent problem worldwide and presents a significant challenge to
the immune system of all mammals and vertebrates. Malignant tumors are especially lethal, with
an uncontrolled growth that metastasizes throughout the body and challenges the host. Malignant
phenotypes of cancers have the ability to evade and challenge cellular mechanisms such as
regulation of cell proliferation, resistance of tumor cells to apoptotic death, ability of tumor cells
to invade host tissues and metastasize to different sites, and evade the host immune defense
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mechanisms (Abbas et al., 2015). A significant portion of research in the immunology field is
dedicated to tumor immunology and to understanding the complexity of the pathways of its
development and complete invasion of a host’s system.
The tumor cells are capable of activating immune responses, specifically within in the
adaptive immunity (Abbas et al., 2015). Histopathology studies give insight to the specific
cellular responses to tumor cells, showing that tumors are surrounded by T lymphocytes (T
cells), natural killer (NK) cells, and macrophages. T cells are the key players in cell-mediated
immunity as they act against viruses and bacteria that are generated inside cells or have been
taken up by cells through phagocytosis and therefore are inaccessible to antibodies. Antibodies
are produced by B-lymphocytes (B cells) and are able to help in the elimination of extra-cellular
antigens during humoral responses. Natural killer cells are specialized innate immunity cells that
act in antiviral defense. Macrophages and neutrophils (called heterophils in birds) are involved in
phagocytizing microbes and killing them by the activation of phagolysosomes.
Unfortunately, immune responses often fail to prevent the growth and spread of tumors
throughout the system, which maintains the urgency for continued research in tumor
immunology. Immune responses often fail due to the weak immunogenicity of tumor antigens
and the immunosuppressive effects tumor cells tend to have on the immune system (Abbas et al.,
2015).
The Arkansas Rous sarcoma Regressor (AR) and Progressor (AP) lines of chickens are
an excellent animal model system for the study of natural regression and progression of tumors,
respectively. Additionally, in the chicken model we can examine cellular immune responses to
tumor-associated antigens in vivo, using the dermis of growing feathers as a tissue test-site. My
research is a novel study examining the types, relative amounts, and time-course of immune cells
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responding to tumor lysates in vivo. Conducting these studies in the AR and AP animal model
will generate important new insight into cellular response in the natural regression and
progression of tumors.
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Literature Review

Characteristics of Arkansas Progressor and Regressor Chicken Lines
The Arkansas Rous Sarcoma Regressor (AR) and Progressor (AP) lines of chickens serve
as a useful animal model for the study of tumor regression and progression. These lines of
chickens were developed by Dr. N. R. Gyles of the University of Arkansas and have been
selected over multiple generations based on their ability to regress and progress Rous Sarcoma
Virus (RSV)-induced tumors, respectively (Gyles et al., 1977). The AR line of chicken was
introduced in 1965 by crossing Giant Jungle Fowl males with White Leghorn females of the
original progressor line that has been maintained at the University of Arkansas for many years
(Gyles et al., 1977). The Giant Jungle Fowl males were obtained from a closed line of Giant
Jungle Fowl that had been reproduced from two males and ten females acquired from Dr. J.N.
Thompson of Pottsville, AR in 1963. These chickens were originally received from the
descendants of ten hatching eggs imported from a backyard flock in Southeast Asia during
World War II (Gyles et al., 1977).
When AP and AR chickens are injected with RSV into the wing-web, birds from both
lines of chickens will develop a tumor. Gyles et al. (1967) and Gyles and Brown (1971)
determined that the AP and AR lines give different responses to the growth of Rous sarcomas.
The AP line permits approximately 90 percent of the sarcomas in the wing-web to grow and kill
the chickens, while in the AR line 70 percent of the sarcomas regress (Gyles et al., 1976). These
significant differences were determined by Gyles to be under genetic influence (Gyles et al.,
1976). The AP and AR lines of chickens are still maintained at the Arkansas Experiment
Station’s Poultry Farm in Fayetteville, AR, under the care of Poultry Geneticist, Dr. Nicholas B.
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Anthony, professor in the Department of Poultry Science. Dr. Anthony further selected the AP
and AR lines for high incidence of progression and regression of RSV-induced tumors,
respectively, and for uniformity of tissue-type (MHC genes) within each line, which allows for
tissue-transfer between AP and AP chickens and AR and AR chickens.
The idea that viruses could be involved in tumor development came about in the early
1900s when it was shown that the RSV caused tumors in chickens (Fields and Knipe, 1990). As
a member of the family Retroviridae, RSV is an acute transforming retrovirus containing v-src
oncogene (Fields and Knipe, 1990). The mechanisms by which viruses can transform cells
involves various proto-oncogenes (cellular in origin) that play no role in the virus life cycle
(Fields and Knipe, 1990).
Rous sarcoma virus is an RNA virus that affects birds, particularly poultry. RSV is
named after Peyton Rous who discovered in 1911 that cancer could be induced in healthy
chickens by injecting them with cell-free extract of the tumor of a RSV infected chicken
(described in Becsei, 2010). Rous sarcoma virus is related to the avian leukosis virus, and is
oncogenic due to the v-src oncogene (Spanakos 2007). Rous sarcoma virus infects cells through
cell surface receptors that are specific for each viral subgroup. The virus uses host cells for
proliferation until many cells are infected with the viral RNA. Following infection of target cells,
the infected cell will be transformed into a cancer cell by the v-src oncogene at the site of
inoculation.
Rous sarcoma can also be induced in chickens using just the v-src DNA. According to
previous studies, chickens that had never been inoculated with the v-src gene had a greater
increase in sarcoma size coupled with a slower regression of sarcoma compared to chickens with
a previous exposure to the v-src DNA (Wisner et al., 1991). This indicates that a primary and
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secondary exposure to tumor antigens resulted in the development of anti-tumor responses, with
characteristics of a memory response (Wisner et al., 1991). How strong this memory response is
and whether or not it can be maintained has not been determined.
T cell-mediated cellular immunity was shown to be most important mediator of immune
responses to tumors (Fleischer and Bauer, 1981). Prat et al. (1987) showed that CD4+ T helper
cells alone provided full protection against v-src induced sarcomas. CD4+ T helper cells are
responsible for orchestrating adaptive immunity, and in the case of anti-tumor responses, the
activity of these cells was found to be positively influenced by cytokines such as interferongamma (INF-γ). INF-γ is a very potent activator of macrophages, boosts natural killer cell
activity, and regulates proliferation and functional differentiation of cytotoxic (CD8+)
lymphocytes (Prat et al., 1987). INF-γ also plays an important role in increasing the expression
of MHC class I molecules which present tumor antigens to cytotoxic T lymphocytes (CTLs)
(Prat et al., 1987). Therefore, INF-γ plays a critical role in making target cells more susceptible
to lysis by tumor-antigen specific CTLs.
Research findings in the response of Japanese quail to RSV induced tumors indicated that
the quail progressor line experienced immune response suppression by malignant cells (Janes et
al., 1994). In this experiment, the progressor line maintained an elevated leukocyte population in
the blood throughout the experiment. In AP and AR lines of chickens that had received a primary
challenge with RSV, Gyles et al. (1967) observed a more rapid recruitment of blood leukocytes
following a secondary RSV exposure in AR compared to AP chickens (Gyles et al., 1967).
However, both lines showed a similar immune response after 15 days, indicating the lines may
eventually maintain a similar response after a longer period of time.
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Immune System Cells and Responses
As discussed previously, the immune system separates into innate and adaptive
immunity, which can be described as the native and acquired immunity. There are several types
of leukocytes, including lymphocytes, granulocytes (heterophils, eosinophils, basophils, mast
cells), monocytes, and macrophages. Lymphocyte and monocytes, or macrophages are also
referred to as mononuclear cells. Innate immunity provides the earliest line of defense against
microbes, and includes cells such as heterophils, macrophages, monocytes, eosinophil, mast cells
and basophils. Heterophils are the avian equivalent to neutrophils in mammals, and mediate the
earliest phase of inflammation. Monocytes, once recruited from the blood to the site of infection,
will differentiate into macrophages. Macrophages are also involved in inflammation, but at a
later phase than heterophils and also remain in the inflamed tissue longer. Heterophils and
macrophages are phagocytes, removing extracellular microbes by taking them inside the cells
where they are killed in phagolysomes. While heterophils are phagocytosing microbes early in
the infection they die very soon and are not as effective as the long-lived macrophages.
Macrophages are specialized phagocytes and with T cell help (IFN-γ) become highly activated
and able to kill microbes that survive inside the phagolysosome (intracellular bacteria).
Additionally, macrophages can present antigens to T helper cells.
Adaptive immunity, which is acquired after an exposure to antigens, involves B and Tlymphocytes. B-lymphocytes produce antibodies and mediate humoral immunity. T-lymphocytes
coordinate cell-mediated immunity and include many different subsets such as CD4+ T helper
cells and CD8+ cytotoxic lymphocytes (CTL).Subsets of T cells are also determined by the type
of antigen-receptor, or T cell receptor (TCR), they express on their surface. Gamma-delta T cells
represent a smaller subset of T cells that possess a TCR consisting of two glycoprotein chains
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called gamma and delta TCR chains on their surface. These T cells act more like cells of innate
immunity in that the specificity of their TCR is limited to frequently encountered microbes.
Additionally, these cells do not require antigen processing into peptides and presentation of
antigen with MHC molecules by antigen-presenting cells. Major histocompatibility complex
(MHC) molecules are specialized proteins that display host cell-associated antigens for
recognition by CD4+ and CD8+ alpha-beta T cells. Alpha-beta T cells have a TCR composed of
two glycoprotein chains called alpha and beta TCR chains. Alpha-beta T cells are the more
sophisticated type of T cell of adaptive immunity with a large repertoire of antigen-specificities
in their TCR. They are highly restricted in antigen-recognition, only being activated if their TCR
can recognize antigen-peptide-MHC complex on antigen presenting cells. Subsets of alpha-beta
T cells include the CD4+ T cells that are restricted to antigen-recognition in association with
MHC class II molecules. Functionally, CD4+ T cells are the T helper cells that orchestrate
adaptive immunity and help other cells of the immune system to become activated. T helper cells
can do this through direct cell-cell contact and/or secretion of cytokines, such as IFN-γ. IFN-γ is
produced in cell-mediated immune responses where it has several functions, including activation
of macrophages with intracellular bacteria and activation of antigen-presenting cells where it
plays an important role of increasing expression of MHC antigens. Another subset of T cells is
the CD8+ T cells that function as the cytotoxic (or killer) cells of adaptive immunity. These cells
are very important in eliminating viral infection and tumor cells – cells that generate antigen in
their cytosol. They typically are alpha-beta T cells that need to recognize antigen-peptide in
association with MHC class I. To become activated they need to recognize their antigen-peptide
MHC class I complex on an antigen presenting cells and receive additional signals from T helper
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cells. Once the CD8+ T cells have differentiated into a killer cells (effector cells; CTL), it can go
to the site of infection or tumor and kill the virus infected /tumor target cells.
The other subset of adaptive immune cells, or B cells, are responsible for producing
antibodies that bind to extracellular microbes and cell surface antigens, block their ability to
infect host cells, and promote microbe/antigen ingestion. B cells mediate humoral immunity and
differentiate into antibody-secreting plasma cells.

Tumor Immunology
The immune system does have the ability to be activated to effectively kill and eradicate
tumors, despite the complexity and sometimes lethality of their nature. A new goal of treatment
of tumors is in fact the use of tumor immunotherapy in which augmentation of the host antitumor response is the goal (Abbas et al., 2015). The very presence of this host anti-tumor
response indicates tumors express antigens that can be recognized by the host as something
foreign. The classifications for these tumor antigens are based on their patterns of expression,
such as tumor-specific antigens and tumor-associated antigens (Abbas et al., 2015). Tumorspecific antigens are antigens expressed on tumor cells but not on normal cells while tumorassociated antigens are antigens that are expressed on tumor cells and normal cells (Abbas et al.,
2015).
Tumors express genes whose products are essential for malignant transformation and for
the maintenance of the malignant phenotype (Abbas et al., 2015). These genes are maintained by
point mutations, deletions, chromosomal translocations, or viral gene insertions affecting cellular
proto-oncogenes or tumor suppressor genes (Abbas et al., 2015). The products of these genes can
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be presented on MHC class I molecules by tumor cells to CD8+ CTL which will then kill the
tumor cells by induction of apoptosis.
There is evidence that adaptive immunity does have the ability to eradicate virus-induced
tumors by preventing the growth of tumors. Certain cancers are more likely to arise in
individuals who are already immunosuppressed, such as in human papilloma virus-associated
(HPV) cervical cancers or AIDS patients. Healthy patients or animals are less likely to
experience tumor development because of their healthy adaptive immune system that is not
currently challenged. This discovery of the ability of the adaptive immune system to combat
tumors is the reason certain vaccines have been developed such as vaccines against HPV for
women and men.
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Objectives
The purpose of this study was to monitor in vivo the type, amount and time-course of
leukocytes responding to syngeneic tumor lysates injected into the dermis of growing feathers in
unsensitized (no RSV) and sensitized (tumor bearing) AP and AR chickens. By evaluating the
cellular infiltration profiles in unsensitized chickens, we can gain insight into the innate response
to the tumor lysate in each line; whereas monitoring these aspects in sensitized chickens will
provide insight into adaptive immune activity. Side by side comparison of the leukocyte
infiltration profiles in unsensitized and sensitized AP vs AR chickens may reveal differences that
allow one line to regress the tumor whereas in the other line the tumor continues to progress.

Hypothesis
We hypothesize that within each line of chickens there will be differences between the
leukocyte infiltration response in unsensitized and sensitized chickens with respect to the timecourse, amount and type of cell responding to the lysate injection. Additionally, side-by-side
comparison of the data may reveal differences in the time-course, amount and type of the
responding leukocytes between AP and AR chickens.

15

Materials and Methods

A.

Experimental Animals
For this study, Arkansas Rous Sarcoma Progressor chickens (AP) and Arkansas Rous
Sarcoma Regressor chickens (AR) were randomly selected from populations maintained by Dr.
Nicholas B. Anthony, Poultry Geneticist, Department of Poultry Science, University of
Arkansas, Division of Agriculture, Fayetteville, AR. Newly hatched, wing-banded chicks were
placed into a floor pen with wood shaving litter at the Arkansas Experiment Station Poultry Farm
in Fayetteville, AR. Chicks were reared following standard vaccination (Marek’s disease),
temperature, lighting, and diet protocols and food and water were available ad libitum. The
wellbeing of the chicks was checked daily. All protocols involving animals were approved by the
University of Arkansas Institutional Animal Care and Use Committee (IACUC Protocol
#11019).

B.

Experimental Design
A total of twenty AR chicks and twenty AP chicks were used. Ten chickens of both groups
were injected intradermal (i. d.) with 100 μL of 700 pfu RSV/mL in PBS at seven weeks of age
in the right wing web (sensitized). Another group of age-matched AR and AP chickens were
injected similarly with the same volume of PBS alone and served as the non-RSV control
(unsensitized). All chickens were monitored for tumor development three times per week. To
determine tumor development, growth, and regression or progression, chicks were examined
visually by the physical appearance of tumors. For each chick, the wing band number was
checked and the tumor was measured (width and length) using a digital caliper (accurate to 0.1
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mm) (Table 1). Measurements were recorded and later given a tumor score based on the criteria
in Table 1. If a tumor had grown visibly large enough to reduce quality of life of a bird, the bird
was euthanized by inhalation of carbon dioxide gas (if less than 6 weeks of age) or injected with
pentobarbital, (65 mg/mL, 1 mL/kg of body weight) and the tumors were removed. Felicity
Johnson, who withdrew from the Honors Program in 2014, carried out the Progressor chicken
work except for the phenotypic analyses of the cells responding to the tumor lysate injected into
the pulp of GF.

Tumor Lysate
To prepare tumor lysates, a progressing RSV-induced tumor and a regressing RSVinduced tumor were collected from one AP and AR chicken, respectively. Under aseptic
conditions, Mr. Robert Dienglewicz removed the capsule and skin of the tumor. The tumor was
cut through the midline and the non-necrotic or “good” tumor tissue was removed based on its
pink color and texture which differs from necrotic tissue. The tumor tissue was cut into small
pieces. Using sterile forceps the pieces were placed in a 20 mL sterile glass homogenizer, PBS
was added and the tissue homogenized on ice. To make the lysate, the homogenized tissue was
then subjected to five freezing/thawing steps in liquid nitrogen and hot water, respectively. This
process was to break the cells into a usable lysate. The protein concentration of the lysates was
then determined using the Bradford protein assay and the concentration of the lysates adjusted to
2.44 mg/mL.
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Table 1. Criteria for determining tumor scores based on measurable size of tumor in wing web.
Scores were determined based on size in both Progressor and Regressor chickens.
Score

Criteria

0

No palpable tumor

1

Up to 50 mm2

2

Between 50 and 100 mm2

3

Between 100 and 200 mm2

4

Between 200 and 300 mm2

5

Between 300 and 400 mm2

6

Between 400 and 500 mm2

7

Between 500 and 600 mm2

8

Between 600 and 700 mm2

9

Death (euthanasia) during study

Injection of Growing Feathers
To monitor leukocyte infiltration in response to tumor lysate, 6 unsensitized AR and AP
chickens and 6 sensitized AR and AP chickens with actively regressing or progressing Rous
sarcoma for at least two weeks were selected for feather injections.
For each chicken, nine 2- to 3-week-old growing feathers (GF) of each breast tract were
selected and marked for injection by cutting off the emerging barbs just above the epidermal cap
surrounding the pulp (dermis). The prepared GF of the unsensitized (U) and sensitized (S) AP
chickens were injected into the pulp with syngeneic AP tumor lysate (2.44 mg protein/mL; 10
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μL/GF; 18 GF/chicken). Similarly, GF of U-AR and S-AR chickens were injected into the pulp
with syngeneic AR tumor lysate (2.44 mg protein/mL; 10 μL/GF; 18 GF/chicken). For all groups
of chickens, GF were collected before (0 d) and 1, 2, 3, 5, and 7 d post-injection. Pulp cell
suspensions were prepared and immunofluorescently stained.

Preparation of Pulp Cell Suspensions and Immunofluorescent Staining
To prepare single cell suspensions from the pulp of injected GF, GF were sliced
longitudinally along the shaft and forceps were used to extract the pulp. A few drops of PBS
were put onto a nylon mesh covering a beaker and then the pulp was placed onto the nylon mesh.
The pulp was pushed through the mesh with a blunt end of a syringe stopper while cold
phosphate-buffered saline (PBS, isotonic solution) was added to cover the pulp. The nylon mesh
has a defined pore size of 60 μm diameter that allows single cell suspensions to be obtained
when pushing tissue through the screen. The contents of the beaker were then added to 130 X 10
mm tubes. The cells prepared from each pulp were then spun at 250 x g (1200 rpm) at 4oC for 10
minutes.
When the cells were washed, the supernatant fluid was discarded. After the supernatant fluid
was discarded, a second wash was conducted. The supernatant fluid was then discarded and the
cells resuspended in 0.4 mL of PBS+. PBS+ consists of 0.1M phosphate buffered saline (pH 7.4)
with 0.1% sodium azide (to prevent cells from internalizing the markers and labels) and 1%
bovine serum albumin (to prevent non-specific binding of specific antibodies). Fifty μL of each
cell suspensions were added to 6 wells in a row of a 96-well round-bottom plate. The cells were
then stained using a panel of mouse anti-chicken (m-a-c) leukocyte-specific monoclonal
antibodies (mAb) following one- or two-color direct immunofluorescent staining procedure. For
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this, 50 µL of fluorescently labeled (FITC and/or PE) mAbs were added to the cells in the
following combinations: PE&FITC labeled isotype control (mouse IgG1 with irrelevant
specificity), m-a-c CD45-FITC (single stain); CD4-FITC & CD8-PE (dual stain); αβTCR-FITC
& MHC class II-PE; γδTCR-FITC & CD8-PE; Bu-1-FITC and Macrophage-PE. All mAb were
purchased from Southern Biotech in Birmingham, Alabama. The isotype control mAbs were
used to detect non-specific binding of fluorescent labeled m-a-c leukocyte specific mAbs and to
decide the cut-off between fluorescence positive and fluorescence negative populations.

Cell Population Analysis by Flow Cytometry
Phenotypic analysis of cells was conducted using a FACSort Becton Dickinson flow
cytometer equipped with an argon laser at 488 nm with detectors for fluorescein isothiocyanate
(FITC), phycoerythrin (PE), and quantum red. For each sample, data from 104 cells were
acquired and analyzed using the CellQuestTM software. For analysis, a dot plot showing forward
scatter (FSC; size) vs. side scatter (SSC; internal complexity) was generated. A region was
drawn around the live cell populations (live cell gate). Another dot plot with FITC fluorescence
intensity on the x-axis and PE fluorescence intensity on the y-axis was drawn to determine the
percentage of each fluorescence-defined leukocyte-subpopulation. Data were expressed as the
percentage of each cell-type in the total pulp cell suspension.

Statistical Analysis
For each line of chicken, Systat computer software was used to conduct two-way analysis of
variance (ANOVA) to determine differences in the effects of time (days post-injections) and
treatment (U vs S) on the qualitative and quantitative nature of the pulp infiltration by leukocytes
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in response to tumor antigens. Tukey’s Honest multiple mean comparisons were conducted to
determine treatment differences at each time-point. Data were expressed as mean ± SEM and
differences with P-values ≤ 0.05 were considered significant.
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Results
Leukocyte Infiltration:
For AP chickens, 2-way ANOVA revealed treatment by day interactions for leukocyte
infiltration (Table 2). Individual mean comparison at each time point revealed higher leukocyte
levels (% pulp cells) on Day 1 and lower levels on Day 7 in sensitized (S) compared to
unsensitized (U) AP chickens (Figure 1a). In both U-AP and S-AP chickens, leukocyte
infiltration peaked at 1-day post-GF injection and returned to pre-injection levels Day 2-5, but
increased again in U-AP chickens on Day 7.
In AR chickens, there were no differences in leukocyte infiltration overall and at
individual time points between U-AR and S-AR chickens (Table 2, Figure 1b). Leukocyte
infiltration levels were elevated on Day 1 and 2 for both AR groups.
Side-by-side comparison of leukocyte infiltration in AR and AP chickens suggests higher
infiltration levels in AP groups on day 1 than in AR groups (Figure 1)

Mononuclear Leukocyte Infiltration:
For AP chickens, 2-way ANOVA revealed treatment by day interactions for mononuclear
cell infiltration (lymphocytes and macrophages) (Table 2). Individual mean comparison at each
time point revealed higher leukocyte levels on Day 1 and lower levels on Day 7 in S-AP
compared to U-AP chickens (Figure 2a). In both AP groups, mononuclear infiltration peaked at
1-day post-GF injection and returned to pre-injection levels Day 3-5, but increased again in UAP chickens on Day 7.
In AR chickens, 2-way ANOVA revealed treatment by day interactions for mononuclear
cell infiltration (Table 2). Individual mean comparison at each time point revealed higher
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mononuclear cell levels on Day 1 in both S-AR and U-AR but returned to pre-injection levels at
day 3 (Figure 2b).
Side-by-side comparison of mononuclear cell infiltration in AR and AP chickens
suggests higher infiltration levels in AP groups on day 1 than in AR groups.

Heterophil Infiltration:
For AP chickens, 2-way ANOVA revealed no treatment by day interactions for
heterophil infiltration and there was no main effect difference between treatments (Table 2).
Individual mean comparison of the two treatment groups at each time point revealed higher
heterophil infiltration on Day 7 in U-AP than S-AP chickens (Figure 3a). In both AP groups,
heterophil infiltration peaked at 1-day post-GF injection and returned to pre-injection levels Day
5, but increased again on Day 7.
In AR chickens, 2-way ANOVA revealed treatment by day interactions for heterophil
infiltration (Table 2). Individual mean comparison of the two treatment groups at each time point
revealed higher heterophil infiltration levels on Day 2 in S-AR compared to U-AR chickens. In
S-AR chickens, heterophil infiltration peaked on Day 2 post-GF injection and then decreased at
Day 3. From Day 3-7 the heterophil infiltration remained elevated above pre-injection levels
(Figure 3b). In U-AR chickens, heterophil infiltration was elevated on Day 1, returned to near
pre-injection levels on Day 2, peaked on Day 3 and remained elevated on Day 5-7 (Figure 3b).
Side-by-side comparison of heterophil infiltration in AR and AP chickens suggests higher
infiltration levels on Day 1 in AP chickens for both groups while the S-AR chickens had higher
infiltration levels on Day 2.
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Macrophage Infiltration:
For AP chickens, 2-way ANOVA revealed no treatment by day interactions for
macrophage infiltration and no overall differences (main effect) between the S-AP and U-AP
chickens (Table 2). Individual mean comparison at each time point revealed higher macrophage
levels on Day 1 in S-AP compared to U-AP chickens (Figure 4a). In both AP groups,
macrophage infiltration peaked at 1-day post-GF injection and returned to pre-injection levels for
Day 3-7.
In AR chickens, 2-way ANOVA revealed no treatment by day interactions for
macrophage infiltration and no effect of treatment was observed between the two groups (Table
2). In the U-AR chickens, macrophage infiltration peaked on Day 1 post-GF injection and was
below pre-injection levels from Day 3-7 (Figure 4b).
Side-by-side comparison of macrophage infiltration in AR and AP chickens suggests
higher infiltration levels in S-AP chickens on Day 1 post injection.

MHC Class II+ Cell Infiltration:
For AP chickens, 2-way ANOVA revealed no treatment by day interactions for MHC
class II+ cell infiltration and no effect of treatment (main effect)(Table 2). Individual mean
comparison at each time point also revealed no differences in percentage of MHC class II+ cells
in S-AP compared to U-AP chickens (Figure 5a). In both AP groups, MHCII+ cells gradually
increased, reaching the highest level by Day 7.
In AR chickens, 2-way ANOVA revealed no treatment by day interactions for MHC class
II+ cell infiltration and no differences (main effect) in % MHC class II+ cells infiltrating the pulp
between S-AR and U-AR chickens (Table 2).For both S-AR and U-AR chickens, infiltration
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levels of MHC class II+ cells peaked on Day 1 and remained at pre-injection levels on Day 3-7
(Table 2, Figure 5b).
Side-by-side comparison of MHC class II+ cell infiltration profiles in AP and AR
chickens suggests lower infiltration levels in AP chickens on Day 1 but higher levels on Day 3-7
compared to AR groups (Figure 5).

B Cell Infiltration:
For AP chickens, 2-way ANOVA revealed no treatment by day interactions for B cell
infiltration and no overall treatment differences (main effect)(Table 2). Individual mean
comparison at each time point revealed lower levels on Day 3 and higher levels Day 5-7 in S-AP
compared to U-AP chickens (Figure 6a). In both AP groups, B cell levels were highest on Day 1
and Day 2 post-GF injection. In U-AP chickens, B cell levels gradually decreased from Day 1-7
to pre-injection levels, whereas in S-AP chickens levels dropped substantially from Day 2 to 3
and remained near pre-injection levels between Day 3 to 7.
In AR chickens, 2-way ANOVA revealed no treatment by day interactions for B cell
infiltration but an overall (main effect) higher B cell infiltration in U-AR compared to S-AR
chickens (Table 2). Individual mean comparison at each time point revealed higher levels in UAR compared to S-AR chickens on Day 2. In both groups of AR chickens B cell infiltration
levels were above pre-injection levels on Day 2-5 (Table 2, Figure 6b).
Side-by-side comparison of B cell infiltration suggests that B cell levels increased earlier
(Day 1 vs. Day 2) and proportionally less (2 fold vs. 6 fold) in AP chickens compared to AR
chickens, respectively. Moreover, the elevated levels of B cells were sustained from Day 2 to 5
in AR chickens (Figure 6).
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T Cell Infiltration:
For AP chickens, 2-way ANOVA revealed no treatment by day interactions for T cell
infiltration and no overall treatment effects (main effect)(Table 2). Individual mean comparison
at each time point revealed higher T cell levels in U-AP compared to S-AP chickens on Day 7
(Figure 7a). In both AP groups, T cell infiltration peaked at 1-Day post-GF injection and then
decreased to pre-injection levels between Day 2-5 in U-AP chickens and Day 2-7 in S-AP
chickens.
In AR chickens, 2-way ANOVA revealed no differences in T cell infiltration between the
two groups of AR chickens and no main effect of treatment (Table 2). In both AR groups, T cell
levels were elevated on Day 1 and Day 2 (Table 2, Figure 7b).
Side-by-side comparison of T cell infiltration revealed that AR chickens had higher and
more sustained initial infiltration (Day 1-2) while AP chickens had higher T cell infiltration on
Day 7 (Figure 7).

Alpha-beta TCR+ T Cell Infiltration:
For AP chickens, 2-way ANOVA revealed no treatment by day interactions for alphabeta TCR+ T cell infiltration and no overall treatment effects (main effect)(Table 2). Individual
mean comparison at each time point revealed higher alpha-beta TCR+ T cell levels on Day 7 in
U-AP compared to S-AP chickens (Figure 8a). In both groups, alpha-beta TCR+ T cell levels
were elevated on Day 1, and returned near to pre-injection levels from Day 2-5 in U-AP and Day
2-7 in S-AP chickens.
In AR chickens, 2-way ANOVA revealed no treatment by day interactions for alpha-beta
TCR+ T cells and no overall treatment effects (main effect)(Table 2). In both groups, alpha-beta
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TCR+ T cell levels peaked on Day 1-2 and returned near pre-injection levels from Day 3-7
(Table 2, Figure 8b).
Side-by-side comparison of alpha-beta TCR+ T cell levels suggests more a higher and
more sustained increase of alpha-beta TCR+ T cells in AR compared to AP chickens (Day 1-2
vs. Day 1).

Gamma-delta T Cell Infiltration:
For AP chickens, 2-way ANOVA revealed no treatment by day interactions and no
overall treatment differences for gamma delta T cell infiltration (main effect)(Table 2) (Figure
9a). In both AP groups, gamma delta T cell infiltration peaked on Day 1 and then returned to preinjection levels Day 2-5 and then increased again on Day 7.
In AR chickens, 2-way ANOVA revealed no treatment by day interactions and no overall
treatment differences for gamma delta T cells (main effect)(Table 2). Individual mean
comparison at each time point revealed greatly elevated gamma delta T cell levels in U-AR
compared to S-AR chickens on Day 2. In both AR groups, gamma delta T cell levels were
elevated on Day 1 and Day 2 (Table 2, Figure 9b).
Side-by-side comparison of gamma delta T cell infiltration suggests greater infiltration of
gamma delta T cells on Day 2 in U-AR compared to AP chickens (Figure 9)

CD4+ T Cell Infiltration:
For AP chickens, 2-way ANOVA revealed treatment by day interactions for CD4+ T cell
infiltration (Table 2). Individual mean comparison at each time point revealed higher CD4+ T
cell levels on Day 7 in U-AP compared to S-AP chickens (Figure 10a). In both AP groups, levels
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of CD4+T cell infiltration decreased from Day 0-2 and then returned to near pre-injection levels
for the remainder of the study.
In AR chickens, 2-way ANOVA revealed no treatment by day interactions and no overall
treatment differences (main effect) for CD4+ T cells (Table 2, Figure 10b). In both AR groups
levels of CD4+ T cells peaked on Day 2 and returned to pre-injection levels thereafter.
Side-by-side comparison suggests a diverging response in terms of T helper cell
infiltration (CD4+) in AP compared to AR chickens with levels decreasing in AP, and increasing
in AR chickens on Day 1 and Day 2 (Figure 10).

CD8+ T Cell Infiltration:
For AP chickens, 2-way ANOVA revealed treatment by day interactions for CD8+ T cell
infiltration (Table 2). Individual mean comparison at each time point revealed higher levels of
CD8+ T cell levels on Day 7 in U-AP compared to S-AP chickens (Figure 11a). In both AP
groups, infiltration of CD8+T cells peaked on Day 1, remained elevated on Day 2, and dropped
to pre-injection levels on Day 3-5 in U-AP and Day 3-7 in S-AP chickens.
In AR chickens, 2-way ANOVA revealed no treatment by day interactions and no overall
treatment differences for CD8+ T cells (main effect)(Table 2). Individual mean comparison at
each time point revealed higher CD8+ T cell levels on Day 2 in U-AR compared to S-AR
chickens (Table 2, Figure 11b). In S-AR and U-AR chickens, CD8+ T cell levels peaked on Day
1 and Day 2, respectively, and returned to pre-injection levels thereafter.
Side-by-side comparison of CD8+ T cell infiltration revealed that AP chickens had higher
CD8+ T cell infiltration at Day 1 and Day 2 than the AR chickens (Figure 11)
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CD4:CD8 Cell Ratio:
For AP chickens, 2-way ANOVA revealed no time by day interactions and no overall
treatment differences for CD4:CD8 ratios (main effect)(Table 2). In both groups, the CD4:CD8
ratio dropped substantially on Day 1 and Day 2 and returned to pre-injection levels thereafter
(Figure 12a).
In AR chickens, 2-way ANOVA revealed no time by day interactions and no overall
treatment differences for CD4:CD8 ratios (main effect)(Table 2). The CD4:CD8 ratios were
slightly elevated on Day 2 and Day 3 in U-AR chickens and gradually increase in S-AR chickens
from Day 1-7 (Table 2, Figure 12b).
Side-by-side comparison suggests a diverging response with CD4:CD8 ratios dropping
substantially on Day 1 and Day 2 and never returning above pre-injection levels in AP chickens,
whereas in AR chickens the ratio increased and remained above pre-injection levels on Day 2-7
(Figure 12).

T Cell:B Cell Ratios
For AP chickens, 2-way ANOVA revealed treatment by day interactions for T cell:B cell
ratios (Table 2). Individual mean comparison at each time point revealed a higher T cell:B cell
ratio levels on Day 7 in U-AP compared to S-AP chickens (Figure 13a). In both AP groups, T
cell:B cell ratios remained near pre-injection levels Day 1-5 in U-AP and Day 1-7 in S-AP
chickens.
In AR chickens, 2-way ANOVA revealed treatment by day interactions for T cell:B cell
ratio (Table 2). Individual mean comparison at each time point revealed higher levels in S-AR
compared to U-AR on Day 7. In both groups, T cell:B cell ratios peaked on Day 1 and then
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dropped to below pre-injection levels on Day 2-5 and then started to increase again on Day 7
(Table 2, Figure 13b)
Side-by-side comparison revealed that AP chickens had substantially lower T cell:B cell
ratios on Day 0, 1, and 7 than AR chickens (Figure 13)
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Table 2. Two way analysis of variance (ANOVA) determining the main effect of treatment (No
RSV and Progressing/Regressing Rous sarcoma), the main effect of day post lysate injection into
growing feathers, and treatment by day interactions1. Growing feathers were injected in the
Arkansas Rous sarcoma progressing (AP) and regressing (AR) chickens.

AP
P-Value

AR
P-Value

Leukocytes
Treatment
Day
Treatment X Day

0.672
< 0.001
< 0.001

0.675
< 0.001
0.304

Mononuclear Cells
Treatment
Day
Treatment X Day

0.505
< 0.001
0.003

0.250
0.010
< 0.001

Heterophils
Treatment
Day
Treatment X Day

0.400
< 0.001
0.287

0.250
0.010
< 0.001

Macrophages
Treatment
Day
Treatment X Day

0.110
< 0.001
0.116

0.916
< 0.001
0.596

MHCII
Treatment
Day
Treatment X Day

0.808
< 0.001
0.094

0.059
< 0.001
0.650

T Cells
Treatment
Day
Treatment X Day

0.292
0.003
0.117

0.083
< 0.001
0.134

Alpha-beta TCR+ T
Cells
Treatment
Day

0.069
0.005

0.407
< 0.001
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Treatment X Day

0.053

0.906

gamma delta T Cells
Treatment
Day
Treatment X Day

0.254
< 0.001
0.734

0.081
< 0.001
0.273

CD4+ Cells
Treatment
Day
Treatment X Day

0.180
< 0.001
0.013

0.070
< 0.001
0.130

CD8+ Cells
Treatment
Day
Treatment X Day

0.445
< 0.001
0.070

0.955
0.115
0.416

CD4:CD8 Ratio
Treatment
Day
Treatment X Day

0.989
< 0.001
0.870

0.293
< 0.001
0.788

T Cell: B Cell Ratio
Treatment
Day
Treatment X Day

0.047
< 0.001
< 0.001

0.018
< 0.001
0.009

1Treatment:

Tumor lysates were prepared from progressing tumors from a progressor (AP) and
regressing tumors from a regressor chicken (AR) (2.44 mg protein/mL). Treatments included
injections of respective tumor lysate (AP lysate into AP chickens; AR lysate into AR
chickens)(10 μL/GF) into growing feathers (12 GF/chicken) of unsensitized AP and AR chickens
(no-RSV) and AP and AR chickens with progressing/regressing Rous sarcoma.
Day: Growing feathers were collected before (0) and 1, 2, 3, 5, and 7 d post injection for
determination of leukocyte infiltration profiles in response to the tumor lysates.
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Figure 1. Proportions of leukocytes in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas Rous
sarcoma Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized;
S-AP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10
μL/GF; 12 GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (sensitized;
S-AR; n=6) were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg
protein/mL; 10 μL/GF; 12 GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions
were prepared and leukocytes identified by immunofluorescent staining using a fluorescently labeled chicken leukocytespecific mouse monoclonal antibody (CD45). Cell population analysis was carried out by flow cytometry. Data shown are
mean SEM; *means within a time point are different (P≤0.05) as determined by Tukey’s multiple means comparison tests.

8

a)

20

*

U-AP
S-AP

15

*

10

5

Mononuclear Cells (% Pulp Cells)

Mononuclear Cells (% Pulp Cells)

20

34

0

b)
U-AR
S-AR

15

10

5

0
0

2

4

6

Days post-feather pulp injection of tumor lysate

8

0

2

4

6

8

Days post-feather pulp injection of tumor lysate

Figure 2. Proportions of mononuclear cells (total lymphocytes and macrophages) in the pulp of growing feathers (GF) injected
with tumor lysate in Arkansas Rous sarcoma Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized; S-AP;
n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6) were
injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions were
prepared and lymphocytes and macrophages identified by immunofluorescent staining using a fluorescently labeled chickenspecific mouse monoclonal antibodies. Cell population analysis was carried out by flow cytometry. Data shown are mean SEM;
*means within a time point are different (P≤0.05) as determined by Tukey’s multiple means comparison tests.
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Figure 3. Proportions of heterophils in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas Rous sarcoma
Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized; SAP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6)
were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions were
prepared. The percentage of heterophils in the pulp cell suspension was determined based on forward and side scatter
characteristics using a flow cytometer. Data shown are mean SEM; *means within a time point are different (P≤0.05) as
determined by Tukey’s multiple means comparison tests.

a)

5

Macrophages (% Pulp Cells)

*

U-AP
S-AP

4

3

2

1

Macrophages (% Pulp Cells)

5

b)
U-AR
S-AR

4

3

2

1

36

0

0
0

2

4

6

Days post-feather pulp injection of tumor lysate

8

0

2

4

6

Days post-feather pulp injection of tumor lysate

Figure 4. Proportions of macrophages in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas Rous
sarcoma Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized;
S-AP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF;
12 GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6)
were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10
μL/GF; 12 GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions
were prepared and macrophages identified by immunofluorescent staining using a fluorescently labeled chicken macrophagespecific mouse monoclonal antibody (KUL01). Cell population analysis was carried out by flow cytometry. Data shown are
mean SEM; *means within a time point are different (P≤0.05) as determined by Tukey’s multiple means comparison tests.
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Figure 5. Proportions of MHCII+ cells in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas Rous
sarcoma Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized; SAP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AP; n=6)
were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10 μL/GF;
12 GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions were
prepared and MHCII+ cells identified by immunofluorescent staining using a fluorescently labeled chicken MHCII-specific
mouse monoclonal antibody (Ia). Cell population analysis was carried out by flow cytometry. Data shown are mean SEM;
*means within a time point are different (P≤0.05) as determined by Tukey’s multiple means comparison tests.
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Figure 6. Proportions of B cells in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas Rous sarcoma
Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized; SAP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6)
were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions were
prepared and B cells identified by immunofluorescent staining using a fluorescently labeled chicken B cell-specific mouse
monoclonal antibody (Bu-1). Cell population analysis was carried out by flow cytometry. Data shown are mean SEM; *means
within a time point are different (P≤0.05) as determined by Tukey’s multiple means comparison tests.
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Figure 7. Proportions of T cells in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas Rous sarcoma
Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized; S-AP;
n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6) were
injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions were
prepared and T cells identified by immunofluorescent staining using a fluorescently labeled chicken T cell-specific mouse
monoclonal antibody (CD3). Cell population analysis was carried out by flow cytometry. Data shown are mean SEM; *means
within a time point are different (P≤0.05) as determined by Tukey’s multiple means comparison tests.

Alpha-beta TCR+ T cells (% Pulp Cells)

40

Alpha-beta TCR+ T Cells (% Pulp Cells)

a)
6
U-AP
S-AP

5

*

4

3

2

1

0
0

2

4

6

Days post-feather pulp injection of tumor lysate

8

6

b)
U-AR
S-AR

5

4

3

2

1

0
0

2

4

6

Days post-feather pulp injection of tumor lysate

Figure 8. Proportions of alpha-beta TCR+ T cells in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas
Rous sarcoma Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized;
S-AP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF;
12 GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6)
were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10
μL/GF; 12 GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions
were prepared and alpha-beta TCR+ T cells identified by immunofluorescent staining using a fluorescently labeled chicken
alpha-beta TCR -specific mouse monoclonal antibody. Cell population analysis was carried out by flow cytometry. Data
shown are mean SEM; *means within a time point are different (P≤0.05) as determined by Tukey’s multiple means
comparison tests.
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Figure 9. Proportions of gamma-delta T cells in the pulp of growing feathers (GF) injected with tumor lysate in
Arkansas Rous sarcoma Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma
(sensitized; S-AP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg
protein/mL; 10 μL/GF; 12 GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (SAR; n=6) were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg
protein/mL; 10 μL/GF; 12 GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell
suspensions were prepared and CD8+ gamma-delta T cells identified by immunofluorescent staining using a
fluorescently labeled chicken gamma-delta T cell-specific mouse monoclonal antibody. Cell population analysis was
carried out by flow cytometry. Data shown are mean SEM; *means within a time point are different (P≤0.05) as
determined by Tukey’s multiple means comparison tests.
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Figure 10. Proportions of CD4+ T cells in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas Rous
sarcoma Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized;
S-AP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF;
12 GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6)
were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10
μL/GF; 12 GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions
were prepared and CD4+ identified by immunofluorescent staining using a fluorescently labeled chicken CD4-specific mouse
monoclonal antibody (T4). Cell population analysis was carried out by flow cytometry. Data shown are mean SEM; *means
within a time point are different (P≤0.05) as determined by Tukey’s multiple means comparison tests.
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Figure 11. Proportions of CD8+ cells in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas Rous sarcoma
Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized; SAP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6)
were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10 μL/GF;
12 GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions were
prepared and CD8+ identified by immunofluorescent staining using a fluorescently labeled chicken CD8-specific mouse
monoclonal antibody (T8). Cell population analysis was carried out by flow cytometry. Data shown are mean SEM; *means
within a time point are different (P≤0.05) as determined by Tukey’s multiple means comparison tests.
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Figure 12. Proportions of CD4 to CD8 ratios in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas Rous
sarcoma Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized; SAP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6)
were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10 μL/GF; 12
GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions were
prepared and CD4 to CD8 ratios calculated by dividing % CD4 by %CD8 (see figure 10 and 11 for CD4 and CD8 profiles). Data
shown are mean SEM; *means within a time point are different (P≤0.05) as determined by Tukey’s multiple means comparison
tests.
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Figure 13. Proportions of T cell to B cell ratios in the pulp of growing feathers (GF) injected with tumor lysate in Arkansas
Rous sarcoma Progressor (AP) and Regressor (AR) chickens.
(a) the pulp of GF of unsensitized AP chickens (U-AP; n=6) and AP chickens bearing progressing Rous sarcoma (sensitized;
S-AP; n=6) was injected with syngeneic tumor lysate prepared from a progressing AP tumor (2.44 mg protein/mL; 10 μL/GF;
12 GF/chicken).
(b) the pulp of GF of unsensitized AR chickens (U-AR; n=6) and AR chickens bearing regressing Rous sarcoma (S-AR; n=6)
were injected into the pulp with syngeneic tumor lysate prepared from a regressing AR tumor (2.44 mg protein/mL; 10
μL/GF; 12 GF/chicken).
For all groups of chickens (a & b) GF were collected before (0) and 1, 2, 3, 5, and 7 d post injection. Pulp cell suspensions
were prepared and T cell to B cell ratios calculated by dividing % T cell by % B cell (see figure 6 and 7 for B and T cell
profiles). Data shown are mean SEM; *means within a time point are different (P≤0.05) as determined by Tukey’s multiple
means comparison tests.

8

Discussion

The Arkansas Rous sarcoma Regressor (AR) and Progessor (AP) chickens develop
tumors following intra-dermal injection of Rous sarcoma virus (RSV) into the wing web. The
most distinguishing feature between the AR and AP lines of chickens is the ability of the AR
chickens to then completely regress and eliminate the tumor whereas the tumors in the AP
chickens will continue to progress. These tumor regression/progression characteristics in AR/AP
chicken make these lines an excellent animal model to examine effective versus ineffective
immune activities in tumor immunology. The few studies carried out on the immune response in
AR and AP chickens suggest a faster and more protective (adaptive memory phenotype) cellmediated anti-tumor response in AR chickens following a second exposure to tumor antigens
(Gyles et al.,1976; Erf et al., 1998, 1999). However, there is no information on the local in vivo
cellular and tissue responses to tumor antigens in AR and AP chickens.
Our lab recently developed an in vivo method that enables monitoring of cellular
responses to antigens in tissues (U.S. Patent No 8,216,551). This method uses growing feathers
(GF) as a dermal test-site to monitor tissue/cellular responses to test-compounds injected into the
feather pulp (dermis). This method involves injection of several GFs at the same time and then
sampling the GFs various times post-injection (minutes, hours, days). Collection of injected GF
is a minimally invasive procedure (GF are not firmly attached to the follicles and can easily be
removed), the GF provide sufficient tissue to carry out several ex vivo analyses, and for the first
time provide insight into the types and relative amounts of immune cells responding to testmaterial, as well as, the time course of the response. Using this in vivo test system, we now have
opportunity to examine the response of unsensitzed (U) and tumor-sensitized (S) AP and AR
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chickens to a first (innate response) and second exposure (adaptive/memory response) to
tumor/RSV antigens. Specifically, my thesis project focused on examining the type, relative
amount, and time-course of various types of leukocytes infiltrating the GF pulp in response to
injection of syngeneic tumor lysates in U-AP compared to S-AP chickens and U-AR compared
to S-AP chickens.
For these types of studies, injection of a tissue-matched (syngeneic, same MHC-type)
lysate is important to avoid generating a tissue-rejection response that would mask the tumor
lysate specific innate and adaptive immune response (Abbas et al, 2015). The MHC type of the
AP chickens is B13/13 while the AR chickens is MHC type B21/21 (Sponakas, 2007). Because of
the different MHC-types in the AR compared to the AP line of chickens, tumor lysate prepared
from an AP progressing tumor was injected into GF of AP chickens, and the lysate prepared
from an AR regressing tumor was injected into GF of AR chickens. With the tissue compatibility
in individuals within a line, the responses observed to the lysate can be interpreted to be
triggered by tumor antigens.
To examine leukocyte infiltration into the pulp of tumor lysate injected GF, pulp cells
suspension were prepared and immunofluorescently stained to identify various types of
leukocyte populations. Cell population analysis was then carried out by flow cytometry to
determine the relative amount (% pulp cell suspension) of the various immune cell populations
infiltrating/present in the pulp at various times post-lysate injection throughout the course of one
week. We hypothesized that within a line of chickens (AP, AR) the types, amount and timecourse of the responding leukocytes would differ between the innate/primary immune response
in U-chickens and adaptive effector/memory response in S chickens.
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For both the AP and AR lines of chickens, however, only few differences were observed
in the leukocyte infiltration profiles between U and S chickens; although two way analysis of
variance revealed treatment (U vs S) by time (days post-lysate injection) interactions indicating
that the two treatment groups responded differently over the time course of the study (Table 2).
For AP chickens, the few quantitative differences in leukocytes infiltration in U-AP compared to
S-AP chickens included lower total leukocyte-, total mononuclear cell- and macrophageinfiltration levels on Day 1 (Figure 1, 2 and 4), and higher total leukocyte-, total mononuclear
cell-, heterophil-, total T cell-, CD4+ T helper cell-, and CD8+ cytotoxic cell-infiltration levels
on Day 7 (Figures 1-3, 8, 10, and 11). The early (Day 1) heightened response of the S-AP
compared and U-AP suggests development of cell-mediated immunity in S-AP chickens to the
tumor lysate. The later (Day 7) heightened infiltration of various T cell subpopulations and
higher T to B cell ratio (Figure 13) in U-AP compared to S-AP suggests development of a
primary cell-mediated immune response in the U-AP chickens and recruitment of effector cells
to the site of lysate injection. Further studies on the functional state of these infiltrating cells are
needed to confirm development of an anti-tumor cell-mediated response in AP chickens and
assess the functional abilities of the responding cells.
For AR chickens, the few quantitative differences in leukocytes infiltration in U-AP
compared to S-AP chickens included lower heterophil-infiltration on Day 2 (Figure 3) and higher
B cell-, gamma-delta T cell-, and CD8+ cytototxic T cell-infiltration on Day 2 (Figure 6, 9 and
11). Additionally, the T to B cell ratio was elevated in both U-AR and S-AR chickens on Day 7,
with higher levels in S-AR chickens (Figure 13). Together, these observations suggest an early
recruitment of lymphocyte population in U-AR chickens, such as B cells, gamma-delta T and
CD8+ lymphocytes that may be part of “innate” immune activities setting the stage for
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appropriate anti-tumor adaptive immune response. Gamma-delta T cells are often considered to
be part of innate immunity and further analysis may reveal the participating B cells to be IgM+
B1 B cell and the CD8+ lymphocytes to be natural killer cells, which would also categorize these
lymphocytes as part of innate immunity (Abbas et al., 2015). Together, these findings do
however suggest a cell-mediated immune activities in AR chickens. Development of cellmediated immunity is further supported by the high T to B cell ratio observed on Day 7 in both
U-AR and S-AR chickens, like representing T effector/memory cell arrival in the target tissue.
Although statistical comparison between AP and AR chickens is not possible, because
the studies were conducted at different times by different individuals, side by side comparisons
between the profiles of responding leukocyte does reveal differences that need further
investigation. Some apparent differences between AP and AR leukocyte infiltration profiles were
observed on Day 1 post-lysate injection when AP chickens had higher levels of total leukocyte-,
total mononuclear cell-, heterophil-, macrophage-, B cell-, and gamma-delta T cell-infiltration
than AR chickens (Figure 1-4, 6 and 9). Other striking differences between AP and AR
infiltration responses to tumor lysates were observed regarding recruitment of T cells. Total T
cell-, alpha-beta TCR+ T cell-, and CD4+ T cell-infiltration was lower in AP then AR chickens
on Day 1 and 2 (Figure 7, 8 and 10), as was the CD4 to CD8 cell ratio on Day 1&2 (Figure 12)
and the T to B cell ratio on Day 1 and 7 post-lysate injection (Figure 13). Together, the early
higher and more sustained infiltration of T cells and the participation of the more “sophisticated”
alpha-beta TCR+ T cells in AR compared to AP chickens supports the concept of an earlier and
qualitatively better cell-mediated anti-tumor response in AR chickens. The most-striking
differences between AP and AR chickens that emerged through side-by-side comparison were
the infiltration profiles of CD8+ cells and CD4+ cells. In AP chicken, relative levels of CD4+ T
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cells dropped substantially below pre-injection levels between Day 0 and 2 (Figure 10 ), whereas
in AR chickens, CD4 + T cell levels increased between Day 0 and 2, reaching peak infiltration
levels on Day 2. Moreover, in AP chickens, levels of CD8+ cell infiltration on Day 1 and 2
(Figure 11) were much higher than those observed in AR chickens. These different infiltration
profiles of CD4+ and CD8+ cells in AP compared to AR chickens are also clearly reflected in
the CD4 to CD8 cell ratio, which was substantially lower in AP chickens than AR chickens on
Day 1 and 2 (Figure 12). Considering the important role of CD4+ T helper cell in orchestrating
and activating an effective cell-mediated immune response, this early divergence in the CD4+
and CD8+ lymphocyte infiltration profiles in AP and AR chickens may well be responsible for
the ineffective anti-tumor response of AP chickens.
Taken together, this descriptive study of the types, amounts and time-course of
leukocytes responding to tumor lystate injected into GF of unsensitized and sensitized AP and
AR chickens, revealed qualitative, quantitative and time-course differences that provide
important new knowledge needed to further examine an effective versus ineffective tumorspecific immune response in this unique chicken model.
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